title: [Dyspnea secondary to pulmonary hypertension in a patient with splenic myeloid metaplasia].
abstract: There are several possible pathophysiological links between the development of pulmonary hypertension and myelofibrosis with myeloid metaplasia. We report a woman with myelofibrosis and myeloid metaplasia who presented with dyspnea and massive, painful splenomegaly. Right heart catheterization evidenced pulmonary hypertension. Her management consisted of splenic irradiation associated to sildenafil. Dyspnea in patients with myelofibrosis and myeloid metaplasia can be secondary to pulmonary hypertension and conversely the differential diagnosis of pulmonary hypertension should include a myeloproliferative syndrome.
authors.affiliation: Département de médecine interne, Hôtel-Dieu de France, boulevard Alfred Naccache, Ashrafieh, Beyrouth, Lebanon. prfghaddad@yahoo.com
authors.forename: F
authors.initials: F
authors.lastname: Haddad
authors.forename: S
authors.initials: S
authors.lastname: Anouti
authors.forename: G
authors.initials: G
authors.lastname: Maalouly
authors.forename: M
authors.initials: M
authors.lastname: Jammal
authors.forename: R
authors.initials: R
authors.lastname: Nemnoum
authors.forename: A
authors.initials: A
authors.lastname: Kettaneh
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use; D006328:Cardiac Catheterization; D003937:Diagnosis, Differential; D004232:Diuretics / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004417:Dyspnea / Q000209:etiology*; D015150:Echocardiography, Doppler; D004562:Electrocardiography; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D005665:Furosemide / Q000008:administration & dosage / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D006976:Hypertension, Pulmonary / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000175:diagnosis; D010166:Palliative Care; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use; D055728:Primary Myelofibrosis / Q000150:complications*; D011687:Purines / Q000008:administration & dosage / Q000627:therapeutic use; D000068677:Sildenafil Citrate; D013158:Splenic Diseases / Q000150:complications*; D013163:Splenomegaly / Q000209:etiology / Q000532:radiotherapy; D013450:Sulfones / Q000008:administration & dosage / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D004232:Diuretics; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; D005665:Furosemide; D000068677:Sildenafil Citrate